Login to Your Account

TransMolecular's Scorpion Drugs Garner $33.2M In Series C Round

By Randall Osborne

Wednesday, March 3, 2004
Talk about failing to feel the sting of tight-financing times. With a brain cancer drug derived from scorpion venom aimed for Phase II trials in the second quarter of this year, TransMolecular Inc. (TMI) raised $33.2 million in a Series C round that the company said will be used for multiple clinical and preclinical studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription